Aardvark Therapeutics Inc. (AARD) has emerged as one of the most closely watched names in the biotech space, with its pipeline targeting obesity and rare genetic disorders. The company's recent clinical updates, strategic alignment with regulators, and strong cash position have set the stage for pivotal milestones in 2026 and beyond.
ARD-101: Expanding Reach in Prader-Willi Syndrome
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com